Of the 617 patients with known diabetes, 301 were treated with metformin, 245 with insulin, 106 with dipeptidyl peptidase four inhibitors, 75 with SGLT2 inhibitors, 47 with glucagon-like peptide one receptor analogues and 38 with sulphonylureas (including repaglinide). The gene discussed is SLC5A2; the disease is diabetes mellitus.